Chang AJ, Autio KA, Roach M, Scher HI. High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 2014;11(6):308–23.
Article
PubMed
PubMed Central
Google Scholar
Sebesta EM, Anderson CB. The surgical Management of Prostate Cancer. Semin Oncol. 2017;44(5):347–57.
Article
PubMed
Google Scholar
Robert Koch Institute (ed.) and the Association of Population-based Cancer Registries in Germany (ed.). Cancer in Germany 2015/2016. 12th edition. Berlin; 2020. https://www.krebsdaten.de/Krebs/EN/Content/Publications/Cancer_in_Germany/cancer_chapters_2015_2016/cancer_germany_2015_2016.pdf?__blob=publicationFile
Fourcade RO, Benedict Á, Black LK, Stokes ME, Alcaraz A, Castro R. Treatment costs of prostate cancer in the first year after diagnosis: a short-term cost of illness study for France, Germany, Italy. Spain and the UK BJU Int. 2010;105(1):49–56.
Article
PubMed
Google Scholar
Quante AS, Ming C, Rottmann M, Engel J, Boeck S, Heinemann V, et al. Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. Cancer Med. 2016;5(9):2649–56.
Article
PubMed
PubMed Central
Google Scholar
Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28(7):1117–23.
Article
PubMed
PubMed Central
Google Scholar
Bastian PJ, Boorjian SA, Bossi A, Briganti A, Heidenreich A, Freedland SJ, et al. High-risk prostate cancer: from definition to contemporary management. Eur Urol. 2012;61(6):1096–106.
Article
PubMed
Google Scholar
D’Amico AV, Whittington R, Bruce Malkowicz S, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. J Am Med Assoc. 1998;280(11):969–74.
Article
Google Scholar
“Interdisciplinary guideline of the quality S3 for the early detection, diagnosis and therapy of the different stages of prostate carcinoma“.https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/. Accessed 19 Nov2020.
Klaassen Z, Singh AA, Howard LE, Feng Z, Trock B, Terris MK, et al. Is clinical stage T2c prostate cancer an intermediate- or high-risk disease? Cancer. 2015;121(9):1414–21.
Article
CAS
PubMed
Google Scholar
National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf. Accessed 25 Sep 2021.
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014; 65(1): 124-37.
Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11(11):1066–73.
Article
CAS
PubMed
Google Scholar
Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008;26(15):2497–504.
Article
CAS
PubMed
Google Scholar
Bolla M, Very C, Long JA. High-risk prostate cancer: combination of high-dose, high-precision radiotherapy and androgen deprivation therapy. Curr Opin Urol. 2013;23(4):349–54.
Article
PubMed
Google Scholar
Pignot G, Maillet D, Gross E, Barthelemy P, Beauval JB, Constans-Schlurmann F, et al. Systemic treatments for high-risk localized prostate cancer. Nat Rev Urol. 2018;15(8):498–510.
Article
CAS
PubMed
Google Scholar
Zapatero A, Guerrero A, Maldonado X, Ana A, Segundo CGS, Cabeza RMA, et al. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(3):320–7.
Article
CAS
PubMed
Google Scholar
Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate Cancer significantly reduces risk of metastases and improves survival: Long-term follow up of a randomized clinical trial. J Urol. 2009;181(3):956–62.
Article
PubMed
PubMed Central
Google Scholar
Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009;27(18):2924–30.
Article
PubMed
Google Scholar
Sargos P, Mottet N, Bellera C, Richaud P. Long-term androgen deprivation, with or without radiotherapy, in locally advanced prostate cancer: updated results from a phase III randomised trial. BJU Int. 2020;125(6):810–6.
Article
CAS
PubMed
Google Scholar
Bandini M, Fossati N, Gandaglia G, Preisser F, Dell’Oglio P, Zaffuto E, et al. Neoadjuvant and adjuvant treatment in high-risk prostate cancer. Expert Rev Clin Pharmacol. 2018;11(4):425–38.
Article
CAS
PubMed
Google Scholar
Dell’Oglio P, Abou-Haidar H, Leyh-Bannurah SR, Tian Z, Larcher A, Gandaglia G, et al. Assessment of the rate of adherence to international guidelines for androgen deprivation therapy with external-beam radiation therapy: a population-based study. Eur Urol. 2016;70(3):429–35.
Article
PubMed
Google Scholar
Swisher-Mcclure S, Pollack CE, Christodouleas JP, Guzzo TJ, Haas NB, Vapiwala N, et al. Variation in use of androgen suppression with external-beam radiotherapy for nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2012;83(1):8–15.
Article
PubMed
Google Scholar
Simonato A, Varca V, Gacci M, Gontero P, De Cobelli O, Maffezzini M, et al. Adherence to guidelines among Italian urologists on imaging preoperative staging of low-risk prostate cancer: results from the MIRROR (multicenter Italian report on radical prostatectomy outcomes and research) study. Ther Adv Urol. 2012;2012:651061.
Google Scholar
“Federal Cancer Registry Data Act (BKRG) 2009.” http://www.gesetze-im-internet.de/bkrg/index.html . Accessed 24 Mar 2021.
Arndt V, Holleczek B, Kajüter H, Luttmann S, Nennecke A, Zeissig SR, et al. Data from population-based Cancer registration for secondary data analysis: methodological challenges and perspectives. Gesundheitswesen. 2020;82(S 01):S62–71.
Article
PubMed
Google Scholar
Center for Cancer Registry Data (ZfKD). https://www.krebsdaten.de/Krebs/DE/Content/Scientific_Use_File/scientific_use_file_node.html . Accessed 21 Nov 2021.
Hager B, Kraywinkel K, Keck B, Katalinic A, Meyer M, Zeissig SR, et al. Increasing use of radical prostatectomy for locally advanced prostate cancer in the USA and Germany: a comparative population-based study. Prostate Cancer Prostatic Dis. 2017;20(1):61–6.
Article
CAS
PubMed
Google Scholar
Bratt O, Folkvaljon Y, Eriksson MH, Akre O, Carlsson S, Drevin L, et al. Undertreatment of men in their seventies with high-risk nonmetastatic prostate cancer. Eur Urol. 2015;68(1):53–8.
Article
PubMed
Google Scholar
Human Mortality Database. https://www.mortality.org/hmd/DEUTNP/STATS/mltper_5x1.txt . Accessed 3 Dec 2020.
Hermann S, Kraywinkel K. Epidemiology of prostate cancer in Germany. Der Onkol. 2019;25:294–303.
Article
Google Scholar
Röllig C, Nothacker M, Wöckel A, Weinbrenner S, Wirth M, Kopp I, et al. Development of the interdisciplinary evidence-based S3 guideline for the diagnosis and treatment of prostate cancer: methodological challenges and solutions. Onkologie. 2010;33(7):396–400.
Article
PubMed
Google Scholar
Kroll LE, Schumann M, Hoebel JLL. Regional health differences – developing a socioeconomic deprivation index for Germany. J Heal Monit. 2017;2(2):98–114.
Google Scholar
GISD-The German Index of Socioeconomic Deprivation 2018. https://github.com/lekroll/GISD . Accessed 29 Jul 2020.
Francke AL, Smit MC, De Veer AJE, Mistiaen P. Factors influencing the implementation of clinical guidelines for health care professionals: a systematic meta-review. BMC Med Inform Decis Mak. 2008;8:38.
Article
PubMed
PubMed Central
Google Scholar
Dahm P, Yeung LL, Chang SS, Cookson MS. A critical review of clinical practice guidelines for the management of clinically localized prostate Cancer. J Urol. 2008;180(2):451–9 discussion 460.
Article
PubMed
Google Scholar
Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61(5):1285–90.
Article
CAS
PubMed
Google Scholar
Bolla M. Current status of combined radiation therapy and androgen suppression in locally advanced prostate cancer: what is the way forward? Eur Urol Suppl. 2010;9(11):788–93.
Article
Google Scholar
Chen YW, Muralidhar V, Mahal BA, Nezolosky MD, Beard CJ, Choueiri TK, et al. Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy. 2016;15(6):695–700.
Article
PubMed
Google Scholar
Wang C, Raldow AC, Nickols NG, Nguyen PL, Spratt DE, Dess RT, et al. Underutilization of androgen deprivation therapy with external beam radiotherapy in men with high-grade prostate Cancer. Eur Urol Oncol. 2021;4(2):327–30.
Article
PubMed
Google Scholar
Mohiuddin JJ, Narayan V, Venigalla S, Vapiwala N. Variations in patterns of concurrent androgen deprivation therapy use based on dose escalation with external beam radiotherapy vs. brachytherapy boost for prostate cancer. Brachytherapy. 2019;18(3):322–31.
Article
PubMed
Google Scholar
Rijksen BLT, Pos FJ, Hulshof MCCM, Vernooij RWM, Jansen H, van Andel G, et al. Variation in the prescription of androgen deprivation therapy in intermediate- and high-risk prostate Cancer patients treated with radiotherapy in the Netherlands, and adherence to European Association of Urology guidelines: a population-based study. Eur Urol Focus. 2021;7(2):332–9.
Article
PubMed
Google Scholar
Griesshammer E, Adam H, Sibert NT, Wesselmann S. Implementing quality metrics in European Cancer centers (ECCs). World J Urol. 2021;39(1):49–56.
Article
PubMed
Google Scholar
Kowalski C, Ferencz J, Albers P, Fichtner J, Wiegel T, Feick G, et al. Quality assessment in prostate cancer centers certified by the German Cancer society. World J Urol. 2016;34(5):665–72.
Article
PubMed
Google Scholar
“Annual report of the certified prostate cancer centers 2021”. https://www.krebsgesellschaft.de/jahresberichte.html . Accessed 27 Jul 2021.
Falchook AD, Basak R, Mohiuddin JJ, Chen RC. Use of androgen deprivation therapy with radiotherapy for intermediate- and high-risk prostate cancer across the United States. JAMA Oncol. 2016;2(9):1236–8.
Article
PubMed
Google Scholar
Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst. 2006;98(12):839–45.
Article
PubMed
Google Scholar
Ong WL, Foroudi F, Evans S, Millar J. Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer. BJU Int. 2017;120(Suppl 3):35–42.
Article
CAS
PubMed
Google Scholar
“Recording the frequency of radiotherapies in Germany - Project 3618S42434”. http://doris.bfs.de/jspui/bitstream/urn:nbn:de:0221-2021010424620/7/2020_BfS_3618S42434.pdf . Accessed 25 Aug 2021.
Beck M, Böhmer D, Aebersold DM, Albrecht C, Flentje M, Ganswindt U, et al. Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer: statement from the DEGRO working group on prostate cancer. Strahlenther Onkol. 2020;196(2):109–16.
Article
PubMed
Google Scholar